NNVC - NanoViricides EV/EBITDA Multiple

Corporate company logo of NanoViricides Inc. (NNVC)

NanoViricides, Inc. (NNVC) is attracting leading virologists by offering them the opportunity to work with cutting-edge infection control methods. The business's success relies on the safety of nanocontainers and the attraction of investment for testing COVID-19 and influenza drugs. This price chart on the GURU.Markets platform with the value 0.00 complements data on stable polymer supplies secured by long-term agreements.

NNVC NanoViricides Corp: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/11/2026
Original product of NanoViricides

Assessing the resilience of NanoViricides, Inc. (NNVC) to market shocks is critical as it implements its nanomedicine developments against influenza and herpes in partnership with global organizations. By analyzing the EV/EBITDA multiple of this capital-intensive business, an investor can see the current ratio of the company's value to its operating profit, enabling the rapid identification of overvalued capital assets and the adjustment of strategy before a shift in the macroeconomic cycle.

Competitors of NanoViricides, Inc.

Gilead Sciences Inc - Enterprise Value to EBITDA Ratio|Cidara - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Novavax, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio curevac.com CVAC|Valneva (VALN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vir Biotechnology Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio SIGA|EV/EBITDA Multiple Emergent Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Atea Pharmaceuticals (AVIR)|Total Company Value to Operating Income Before Depreciation Ratio invivyd.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Enanta Pharmaceuticals, Inc. ENTA|INO: Enterprise Value to Operating Income Before Depreciation|HilleVax Corp - EV/EBITDA Multiple|KLRS - EV/EBITDA Multiple|dyadic.com (DYAI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation TLPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cocrystal Pharma|Company Value to EBITDA Traws Therapeutics TRAW|Enterprise Value to EBITDA Ratio DWTX (Dogwood Therapeutics, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization QLGN (Qualigen Corp)|EV/EBITDA Multiple ALVR (AlloVir)|Total Company Value to Operating Income Before Depreciation Ratio VBI Vaccines, Inc. (VBIV)|VIRI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VXRT (Vaxart, Inc.)